Relay Therapeutics Prices $296.8M Public Offering at $12.00/Share
RLAY has more than doubled off its 52-week low of $2.75 on elevated volume (3.0× avg).
Summary
Relay Therapeutics secured $296.8 million in net proceeds from a public offering of 26,354,167 shares of common stock priced at $12.00 per share, including the full exercise of the underwriters' option.
Key Events · Financing and Capital Events · RLAY
-
Public Offering Priced
Relay Therapeutics priced an underwritten public offering of 22,916,667 shares of common stock at $12.00 per share. The underwriters fully exercised their 30-day option to purchase an additional 3,437,500 shares, bringing the total to 26,354,167 shares.
-
Significant Capital Raise
The company expects to receive approximately $296.8 million in net proceeds from the offering, after deducting underwriting discounts and estimated offering expenses.
-
Funding for Pipeline Advancement
This capital infusion is critical for advancing the company's drug development programs, particularly following recent positive clinical data and a Breakthrough Therapy designation for its lead candidate, zovegalisib.
-
Dilution at a Discount
The offering is dilutive to existing shareholders and priced at $12.00 per share, representing a discount to the current market price of $13.72.
Analysis · RLAY · Life Sciences
Relay Therapeutics has finalized a significant public offering, raising approximately $296.8 million in net proceeds. This capital raise, priced at a discount to the current market, is crucial for funding the company's operations and advancing its drug pipeline, especially following recent positive clinical data and a Breakthrough Therapy designation for zovegalisib. While dilutive, it strengthens the company's financial position and extends its cash runway.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLAY was trading at $13.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $2.75 to $17.32. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.